Literature DB >> 8583822

Human cytokine responses to cardiac transplantation and coronary artery bypass grafting.

S Wan1, A Marchant, J M DeSmet, M Antoine, H Zhang, J L Vachiery, M Goldman, J L Vincent, J L LeClerc.   

Abstract

Cardiac surgery with cardiopulmonary bypass triggers an inflammatory response involving proinflammatory cytokines such as tumor necrosis factor-alpha, interleukin-6, and interleukin-8. To elucidate the pathophysiology of this cytokine response, we explored the possible differences in cytokine responses between patients undergoing heart transplantation and those undergoing coronary artery bypass grafting. Plasma levels of tumor necrosis factor-alpha, interleukin-6, interleukin-8, and interleukin-10 were measured in eight patients undergoing heart transplantation (mean age 44 years) and eight patients undergoing coronary artery bypass grafting (mean age 61 years). Duration of cardiopulmonary bypass and ischemic time were both longer in the heart transplantation group than in the coronary artery bypass grafting group (133 +/- 26 min vs 100 +/- 31 min, p < 0.05, and 130 +/- 47 min vs 58 +/- 21 min, p < 0.005, respectively). Samples were collected before heparin administration, at aortic crossclamping and declamping, and at 0.5, 1, 1.5, 2, 4, 12, and 24 hours after declamping. Tumor necrosis factor-alpha levels were significantly higher 30 minutes after aortic declamping in the heart transplantation group than in the coronary artery bypass grafting group (68 +/- 30 vs 18 +/- 5 pg/ml, p < 0.05). Interleukin-6 and interleukin-8 levels were also significantly higher 90 minutes after declamping in patients undergoing heart transplantation than in those undergoing coronary artery bypass grafting (310 +/- 63 vs 169 +/- 24 pg/ml, p < 0.05, and 73 +/- 17 vs 24 +/- 5 pg/ml, p < 0.01, respectively). Furthermore, interleukin-6 and interleukin-8 values 90 minutes after declamping were significantly correlated with the ischemic time (r = 0.72 and r = 0.82, respectively, both p < 0.05). Interleukin-10 levels in both groups rose to reach a peak value of around 115 pg/ml 1 hour after declamping. Patients undergoing heart transplantation exhibited a second peak of tumor necrosis factor-alpha, interleukin-8, and interleukin-10 levels 12 hours after declamping, probably related to the administration of rabbit antihuman thymocyte immunoglobulin (Thymoglobuline) 3 hours after declamping. Interleukin-6 levels decreased more significantly 12 and 24 hours after declamping in patients undergoing heart transplantation, probably related to methylprednisolone therapy. In conclusion, cardiopulmonary bypass is associated with the production of both proinflammatory and antiinflammatory cytokines. The production of proinflammatory cytokines in patients undergoing heart transplantation is higher than that in patients undergoing coronary artery bypass grafting, and this increase could be related to the longer duration of ischemia in the former group. The later course of cytokine levels after heart transplantation may be further influenced by immunosuppressive therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8583822     DOI: 10.1016/s0022-5223(96)70458-0

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  16 in total

1.  Inflammatory cytokines determine the susceptibility of human CD8 T cells to Fas-mediated activation-induced cell death through modulation of FasL and c-FLIP(S) expression.

Authors:  Anna von Rossum; Randall Krall; Nichole K Escalante; Jonathan C Choy
Journal:  J Biol Chem       Date:  2011-04-25       Impact factor: 5.157

2.  In-hospital herpes simplex encephalitis after open heart surgery: an emerging pathology or an under-recognised condition?

Authors:  Mohamed Saleh
Journal:  BMJ Case Rep       Date:  2013-07-10

3.  Risk assessment and outcomes of vasoplegia after cardiac surgery.

Authors:  Athanasios Tsiouris; Lynn Wilson; Ala S Haddadin; James J Yun; Abeel A Mangi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2017-06-13

4.  Multisystemic production of interleukin 10 limits the severity of acute pancreatitis in mice.

Authors:  J L Van Laethem; R Eskinazi; H Louis; F Rickaert; P Robberecht; J Devière
Journal:  Gut       Date:  1998-09       Impact factor: 23.059

5.  Case report of high-dose hydroxocobalamin in the treatment of vasoplegic syndrome during liver transplantation.

Authors:  S Sandy An; C Patrick Henson; Robert E Freundlich; Matthew D McEvoy
Journal:  Am J Transplant       Date:  2018-04-02       Impact factor: 8.086

6.  Evidence of systemic cytokine release in patients undergoing cardiopulmonary bypass.

Authors:  Jeffrey Halter; Jay Steinberg; Gregory Fink; Charles Lutz; Anthony Picone; Rubie Maybury; Nathan Fedors; Joseph DiRocco; Hsi-Ming Lee; Gary Nieman
Journal:  J Extra Corpor Technol       Date:  2005-09

7.  Effects of protective and conventional mechanical ventilation on pulmonary function and systemic cytokine release after cardiopulmonary bypass.

Authors:  Ozge Koner; Serdar Celebi; Huriye Balci; Gurkan Cetin; Kamil Karaoglu; Nahit Cakar
Journal:  Intensive Care Med       Date:  2004-01-13       Impact factor: 17.440

8.  Effect of a polymorphonuclear elastase inhibitor (sivelestat sodium) on acute lung injury after cardiopulmonary bypass: findings of a double-blind randomized study.

Authors:  Masahiro Ryugo; Yoshiki Sawa; Hiroshi Takano; Goro Matsumiya; Shigemitsu Iwai; Masamichi Ono; Hiroki Hata; Takashi Yamauchi; Masaji Nishimura; Yuji Fujino; Hikaru Matsuda
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

Review 9.  Role of cytokines and inflammation in heart function during health and disease.

Authors:  Monika Bartekova; Jana Radosinska; Marek Jelemensky; Naranjan S Dhalla
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

10.  Dextran-70 to modulate inflammatory response after cardiopulmonary bypass: potential for a novel approach?

Authors:  Tobias Schuerholz; Gernot Marx
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.